GlassScriptPhysician profile
Minh Nguyen
NPI 1003801853
$2,723.89
in general payments reported to CMS, 2019-2025
22 companies · $37.89 in 2025
The $37.89 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $288 · 2021: $609 · 2022: $328 · 2023: $884 · 2024: $125 · 2025: $37.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $531.66 | 2019-2024 | Brilinta, Lokelma, Farxiga |
| Janssen Pharmaceuticals, INC | $339.53 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $314.29 | 2021-2023 | Nexletol |
| Edwards Lifesciences Corporation | $205.54 | 2019-2021 | |
| Medtronic, INC. | $167.45 | 2023 | Corevalve Evolut R |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.69 | 2023 | Jardiance, Glyxambi, Tradjenta |
| Abbott Laboratories | $136.39 | 2019 | |
| Amarin Pharma, INC. | $125.00 | 2020 | |
| Inspire Medical Systems, INC. | $124.80 | 2022 | |
| Boston Scientific Corporation | $120.98 | 2020 | |
| Merck Sharp & Dohme LLC | $90.72 | 2022-2023 | Verquvo, Steglatro |
| Pfizer INC. | $90.57 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $57.39 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $49.48 | 2023 | Eliquis |
| Mannkind Corporation | $42.84 | 2023 | Afrezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $41.71 | 2020 | |
| Sanofi-Aventis U.S. LLC | $32.96 | 2021-2023 | |
| Novo Nordisk INC | $32.12 | 2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $23.29 | 2022 | |
| Dexcom, INC. | $21.49 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $17.80 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $15.19 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minh Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.